Ionis Pharmaceuticals (IONS) vs Liquidia (LQDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Liquidia (LQDA) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 87.0% versus a loss of 65.1%. Over five years, LQDA leads with a +1224.3% price change compared with -8.5% for IONS. Liquidia is the larger company by market cap ($4.90 billion vs $4.43 billion), about 1.1 times the size.
Ionis Pharmaceuticals converts more of its revenue into profit, with a net margin of -40.4% versus -43.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IONS | LQDA |
|---|---|---|
| Share price | $26.58 | $54.43 |
| Market cap | $4.43B | $4.90B |
| 1-day change | -2.35% | -3.88% |
| YTD return | -66.40% | +57.81% |
| 1-year return | -65.07% | +86.98% |
| 5-year return | -8.50% | +1224.33% |
| Forward P/E | — | 15.12 |
| EPS (TTM) | $-3.35 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $943.71M | $158.32M |
| Revenue growth (YoY) | +33.83% | +1031.18% |
| Net income (latest FY) | $-381.39M | $-68.92M |
| Gross margin | 98.31% | — |
| Operating margin | -40.45% | -32.45% |
| Net margin | -40.41% | -43.53% |
| 52-week high | $86.74 | $93.61 |
| 52-week low | $26.53 | $22.31 |
| Distance from 52-week high | -69.36% | -41.85% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +155.19% | +21.50% |
| Average volume | 3.91M | 3.52M |
| Shares outstanding | 166.55M | 90.11M |
| Employees | 1,485 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LQDA has outperformed IONS by 152.0 percentage points over the past year.
- Liquidia grew revenue faster in its latest fiscal year (+1031.18% vs +33.83%).
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,485 employees
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
IONS vs LQDA FAQ
Which is bigger, Ionis Pharmaceuticals or Liquidia?
Liquidia (LQDA) is larger, with a market capitalization of $4.90B compared with $4.43B for Ionis Pharmaceuticals (IONS).
Which stock has performed better over the past year, IONS or LQDA?
LQDA returned +86.98% over the past 12 months, compared with -65.07% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Ionis Pharmaceuticals and Liquidia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.